{"organizations": [], "uuid": "d89c0752ccd55c56d84ae38fa7d075e80bafab3d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s2.reutersmedia.net/resources/r/?m=02&d=20180410&t=2&i=1249785055&w=1200&r=LYNXMPEE3900I", "site_section": "https://www.reuters.com/finance/deals", "section_title": "Deals News | Reuters", "url": "https://www.reuters.com/article/us-samsung-bioepis-stocks-samsung-c-t-co/samsung-ct-shares-rise-after-report-of-planned-stake-purchase-in-biopharma-affiliate-idUSKBN1HH00Y", "country": "US", "domain_rank": 408, "title": "Samsung C&T says no plan currently to buy a stake in biopharma affiliate", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-04-10T08:21:00.000+03:00", "replies_count": 0, "uuid": "d89c0752ccd55c56d84ae38fa7d075e80bafab3d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/us-samsung-bioepis-stocks-samsung-c-t-co/samsung-ct-shares-rise-after-report-of-planned-stake-purchase-in-biopharma-affiliate-idUSKBN1HH00Y", "ord_in_thread": 0, "title": "Samsung C&T says no plan currently to buy a stake in biopharma affiliate", "locations": [], "entities": {"persons": [{"name": "haejin choi", "sentiment": "none"}, {"name": "hyunjoo jin", "sentiment": "none"}, {"name": "muralikumar anantharaman", "sentiment": "none"}], "locations": [{"name": "seoul", "sentiment": "none"}, {"name": "south korea", "sentiment": "none"}, {"name": "seoul", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "samsung c&t corp", "sentiment": "negative"}, {"name": "samsung c&t", "sentiment": "negative"}, {"name": "samsung bioepis co", "sentiment": "none"}, {"name": "samsung", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SEOUL (Reuters) - Samsung C&T Corp ( 028260.KS ) said on Tuesday it has no plan currently to purchase shares in Samsung Bioepis Co, after a report said the company is considering raising up to 3 trillion won ($2.8 billion) to buy a 30 percent stake in its biopharma affiliate.\nFILE PHOTO: Employees are reflected on a logo of Samsung C&T Corp at the company's headquarters in Seoul, South Korea, July 16, 2015. REUTERS/Kim Hong-Ji “Samsung C&T is reviewing various measures to secure growth engine for the future, but the firm is not planning at the moment to buy a stake in Samsung Bioepis,” Samsung C&T said in a statement.\nReporting by Haejin Choi; Editing by Hyunjoo Jin; Editing by Muralikumar Anantharaman\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-10T08:21:00.000+03:00", "crawled": "2018-04-10T09:25:37.031+03:00", "highlightTitle": ""}